Cardiovascular risk prediction in healthy older people

Johannes T Neumann1,2,3, Le T P Thao4, Emily Callander4

  • 1Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria, 3004, Australia. j.neumann@uke.de.

Geroscience
|November 11, 2021
PubMed

Insights

A new model identifies major adverse cardiovascular events (MACE) risk in healthy older adults using factors like age, sex, and kidney function. This algorithm aids in predicting cardiovascular events in the elderly population.

Area of Science:

  • Cardiology
  • Geriatrics
  • Preventive Medicine

Background:

  • Identifying individuals at high risk for major adverse cardiovascular events (MACE) is crucial for preventive strategies.
  • Existing risk prediction algorithms often lack specific validation for the elderly population.
  • There is a need for accurate tools to assess cardiovascular risk in healthy older adults.

Purpose of the Study:

  • To develop and validate a predictive model for 5-year incident MACE in healthy individuals aged 70 years and older.
  • To identify key predictors of MACE in this specific demographic using both prior evidence and machine learning.
  • To assess the model's performance through internal and external validation.

Main Methods:

  • Analysis of data from a randomized trial of 18,548 participants (≥70 years) and external validation in 25,138 primary care individuals.
  • MACE definition included coronary heart disease death, ischemic stroke, or myocardial infarction.
  • Cox regression and machine learning were employed to identify predictors and build the risk model, with performance evaluated using Area Under the Curve (AUC).

Main Results:

  • The final model incorporated age, sex, smoking, systolic blood pressure, HDL-c, non-HDL-c, serum creatinine, diabetes, and antihypertensive use.
  • Machine learning identified age, sex, and creatinine as the most significant predictors.
  • The model achieved an AUC of 68.1% in the primary cohort, 67.5% in internal validation, and 64.2% in external validation, demonstrating good risk discrimination but underestimating absolute risk externally.

Conclusions:

  • A predictive model incorporating established and novel risk factors, notably renal function, can identify incident MACE risk in healthy elderly individuals.
  • The model effectively ranks risk but requires calibration for accurate absolute risk prediction in diverse populations.
  • The findings highlight the importance of considering renal function in cardiovascular risk assessment for older adults.

Related Concept Videos

Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
512
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
390
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
397
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
476
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
259
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63